(14442117), S. A., (492657), A. R., (14442120), R. M., (14442123), A. K., (2610634), S. Q., (290256), A. P., . . . (79420), S. D. (2023). Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Chicago Style (17th ed.) Citation(14442117), Shayista Akbar, et al. Circulating Exosomal Immuno-oncological Checkpoints and Cytokines Are Potential Biomarkers to Monitor Tumor Response to Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer Patients. 2023.
MLA (9th ed.) Citation(14442117), Shayista Akbar, et al. Circulating Exosomal Immuno-oncological Checkpoints and Cytokines Are Potential Biomarkers to Monitor Tumor Response to Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer Patients. 2023.